• 1
    Seikaly M, Ho PL, Emmett L, Tejani A. The 12th Annual Report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS): renal transplantation from 1987 through 1998. Pediatr Transplant 2001; 5: 215231.
  • 2
    Vella JP, Knoflack A, Waaga AM, Sayegh MGT. T cell mediated immune responses in chronic rejection. Role of indirect allorecognition and costimulation. Graft 1998; 1 (Suppl. II): 1117.
  • 3
    Braun YM, McCormack A, Webb G, Batchelor JR. Mediation of acute but not chronic rejection of MHC-incompatible rat kidney grafts by alloreactive CD4 cells activated by the direct pathway of sensitization. Transplantation 1993; 55: 177182.
  • 4
    Lee RS, Sayegh MH. Allorecognition pathways. In: Tejani AH, Harmon WE, Fine RN, eds. Pediatric Solid Organ Transplantation. Copenhagen: Munksgaard; 2000. pp 1725.
  • 5
    Matas AJ. Risk factors for chronic rejection-a clinical perspective. Transplant Immunol., 1998; 6: 111.
  • 6
    Taal MW, Tilney NL, Brenner BM, Mackenzie HA. Renal mass: an important determinant of late allograft outcome. Transplant Rev., 1998; 12: 7484.
  • 7
    Brenner BM, Cohen RA, Milford EL. In renal transplantation, one size may not fit all. J Am Soc Nephrol 1992; 3: 162169.
  • 8
    Terasaki PI, Koyama H, Cecka IM, Gjertson DW. The hyperfiltration hypothesis in human renal transplantation. Transplantation 1994; 57: 14501454.
  • 9
    Chertow GM, Milford EL, Mackenzie HS, Brenner BM. Antigen-independent determinants of cadaveric kidney transplant failure. J Am Med Assoc 1996; 276: 17321736.
  • 10
    Chertow GM, Brenner BM, Mackenzie MM, Milford EL. Antigen-independent determination of graft survival in living-related kidney transplantation. Kidney Int 1997; 63 (Suppl.): S84S86.
  • 11
    Humar A, Kandaswamy R, Hassoun AA et al. Immunologic factors-the major risk for tong-term renal allograft survival. Transplantation 1999; 68: 18421846.
  • 12
    Almond PS, Matas AJ, Gillingham KJ et al. Lessons learned and future hopes. Three thousand renal transplants. In: Terasaki PI, ed. Clinical Transplants 1990. Los Angeles, CA: UCLA Tissue Typing Laboratory; 1991. p. 217.
  • 13
    Massy ZA, Guijarro C, Wiederkehz MR, Ma JZ, Kasiske BL. Chronic allograft rejection: immunologic and non-immunologic risk factors. Kidney Int 1996; 49: 518.
  • 14
    Guyor C, Nguyen JM, Cochat P et al. Risk factors for chronic rejection in pediatric renal allograft recipients. Pediatr Nephrol 1996; 10: 723727.
  • 15
    Tejani A, Sullivan EK. The impact of acute rejection on chronic rejection: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Pediatr Transplant 2000; 4: 107111.
  • 16
    Tejani A, Sullivan EK, Fine RN, Harmon WE, Alexander SR. Steady improvement in renal allograft survival among North American children. A five-year appraisal by the North American Pediatric Renal Transplant Cooperative Study. Kidney Int 1995; 48: 551553.
  • 17
    Feld LG, Stablein DM, Fivush BA, Harmon WE, Tejani A. Renal transplantation in children from 1987 to 1996. The Annual Report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Pediatr Transplant 1997; 1: 146162.
  • 18
    Benfield MR, Stablein DM, Tejani A. Trends in immunosuppressive therapy: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Pediatr Transplant, 1999; 3: 2732.
  • 19
    Elshihabi I, Chavers B, Donaldson L, Emmett L, Tejani A. Continuing improvement in cadaver donor graft survival in North American children: The 1998 Annual Report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Pediatr Transplant 2000; 4: 235246.
  • 20
    Matas AJ. Impact of acute rejection on development of chronic rejection in pediatric renal transplant recipients. Pediatr Transplant 2000; 4: 9299.
  • 21
    Kasiske BL. Risk factors for accelerated atherosclerosis in renal transplant recipients. Am J Med 1998; 84: 985.
  • 22
    Singh A, Tejani C, Benfield MR, Tejani A. Sequential analysis of the lipid profile of children post-renal transplantation. Pediatr Transplant 1998; 2: 216.
  • 23
    Harmon WE, Sullivan EK. Cyclosporine dosing and its relationship to outcome in pediatric renal transplantation. Kidney Int 1993; 44 (2): S50S55.
  • 24
    Tejani A, Sullivan EK. Higher maintenance cyclosporine dose decreases the risk of graft failure in North American children. A report of The North American Pediatric Renal Transplant Cooperative Study. JASN 1996; 7: 550555.
  • 25
    Solez K, Axelsen RA, Benediktsson H et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection The Banff working classification of kidney transplant pathology. Kidney Int, 1993; 44: 411422.
  • 26
    Suthanthiran M. Acute rejection of renal allografts: Mechanistic insights and therapeutic options. Kidney Int 1997; 51: 12891304.
  • 27
    Pavlakis M, Lipman M, Strom TB. Intragraft expression of T-cell genes in human renal allograft rejection. Kidney Int 1996; 49 (2): S7S12.
  • 28
    Sharma VK, Bologa RM, Xu G-P et al. Intragraft TGF-_1 mRNA. A correlate of interstitial fibrosis and chronic allograft nephropathy. Kidney Int 1996; 49: 12971303.
  • 29
    Harmon WE, Stablein DM, Tejani AA. Rejection-free milieu provides accelerated growth, better graft function and superior graft survival in children. Presented at Transplant 2001, American Society of Transplantation, Chicago, May 2001.